N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study
et al., Infectious Diseases,
Retrospective 42 hospitalized PCR+ COVID-19 pneumonia patients treated with NAC, and a matched control group of 40 patients, showing significantly lower severe respiratory failure and significantly lower mortality with treatment. NAC 600 mg bid orally for 14 days.
risk of death, 97.1% lower, RR 0.03, p = 0.006, treatment 2 of 42 (4.8%), control 12 of 40 (30.0%), NNT 4.0, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes.
Assimakopoulos et al., 6/29/2021, retrospective, Greece, Europe, peer-reviewed, 9 authors, study period 1 February, 2021 - 30 April, 2021.